Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: A population-based cohort study in Taiwan

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 8, 2010, Pages 786-791

  Hsiao, Fei Yuan ^a,b   Tsai, Yi Wen ^a,c   Wen, Yu ^d   Chen, Pei Fen ^c   Chou, Hao Yu ^e   Chen, Chen Huan ^a   Kuo, Ken N ^c   Huang, Weng Foung ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e Bureau of National Health Insurance Taiwan   (Taiwan)

Author keywords

Heart failure; Mortality; Readmission; Sulfonylurea (SU); Thiazolidinediones (TZD)

Indexed keywords

GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

AGED; ARTICLE; COHORT ANALYSIS; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG EXPOSURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION GROUPS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77956643121     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1999     Document Type: Article

References (15)

1. US Food and Drug Administration. Summary for Actos and Avandia, April 26, 2002. Available at: http://www.fda.gov/medwatch/safety/2002/summary-actos- avandia.pdf. Accessed September 20, 2007.
2. Takeda Pharmaceuticals. Actos prescribing information, 2002. Available at: http://www.actos.com/pi.pdf. Accessed September 20, 2007.
3. GlaxoSmithKline Pharmaceuticals. Avandia prescribing information, 2002. Available at: http://us.gsk.com/products/assets/us-avandia.pdf. Accessed September 20, 2007.
4. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Med Assoc J 2002; 166: 219.
5. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003; 108: 2941-2948.
6. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263.
7. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26: 2983-2989.
8. Rejapolan R, Rosenson RS, Fernades AW, et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004; 26: 1400-1410.
9. Karter AJ, Ahmen AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabetes Med 2005; 22: 986-993.
10. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Car 2005; 28: 20-26.
11. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590.
12. Bureau of National Health Insurance. National Health Insurance in Taiwan. 2007. Available at: http://www.nhi.gov.tw/english/index.asp. Accessed April 20, 2010.
13. The ATC and DDD system. 2008. WHO Collaborating Centre for Drug Statistics Methodology Website. Available at: http://www.whocc.no/atcddd/. Accessed September 29, 2008.
14. US Food and Drug Administration. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) Information, 2007. Available at: http://www.fda.gov/cder/drug/infopage/rosiglitazone/default.htm. Accessed April 2, 2008.
15. US Food and Drug Administration. Pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact) Information, 2007. Available at: http://www.fda.gov/ cder/drug/infopage/pioglitazone/default.htm. Accessed April 2, 2008.